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Abstract
Objectives We evaluated the feasibility of using chemical
shift gradient-echo (GE) in- and opposed-phase (IOP) imag-
ing to grade glioma.
Methods A phantom study was performed to investigate the
correlation of 1H MRS-visible lipids with the signal loss ratio
(SLR) obtained using IOP imaging. A cross-sectional study
approved by the institutional review board was carried out in
22 patients with different glioma grades. The patients
underwent scanning using IOP imaging and single-voxel
spectroscopy (SVS) using 3T MRI. The brain spectra
acquisitions from solid and cystic components were obtained
and correlated with the SLR for different grades.
Results The phantom study showed a positive linear correla-
tion between lipid quantification at 0.9 parts per million (ppm)
and 1.3 ppm with SLR (r=0.79–0.99, p<0.05). In the clinical
study, we found that SLR at the solid portions was the best
measure for differentiating glioma grades using optimal cut-
points of 0.064 and 0.086 with classification probabilities for
grade II (SII=1), grade III (SIII=0.50) and grade IV (SIV=
0.89).
Conclusions The results underscore the lipid quantification
differences in grades of glioma and provide a more compre-
hensive characterization by using SLR in chemical shift GE
IOP imaging. SLR in IOP sequence demonstrates good per-
formance in glioma grading.
Key Points
• Strong correlation was seen between lipid concentration and
SLR obtained using IOP
• IOP sequence demonstrates significant differences in signal
loss within the glioma grades
• SLR at solid tumour portions was the best measure for
differentiation
• This sequence is applicable in a research capacity for glioma
staging armamentarium
Keywords Lipid phantom .Magnetic resonance
spectroscopy . Volume under the receiver operating curve
surface . Glioma classification . In- and opposed-phase
imaging
Introduction
Glioma describes any tumour arising from the interstitial tis-
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directs further management and determines the prognosis of
the patient. Brain biopsy for histopathologic grading is cur-
rently the gold standard for the grading of gliomas. However,
it is an invasive procedure and poses certain risks to patients,
such as infection and bleeding, in addition to the inherent
possibility of sampling error during biopsy. One of the main
concerns with stereotactic biopsy, particularly with regard to
gliomas, is the accuracy of the histological results, considering
the occurrence of heterogeneity within the tumour itself. Mag-
netic resonance imaging (MRI) is an established technique for
biopsy planning and characterization of gliomas [2]. MRI has
the ability to image the entire lesion and the adjacent brain
tissue for glioma evaluation, and provides valuable informa-
tion, including contrast enhancement, oedema, haemorrhage,
necrosis, and mass effect, for characterization of tumour ag-
gressiveness. Uptake of contrast in the tumour indicates
blood–barrier breakdown or neovascularity, which is a feature
of high-grade glioma. Grading of gliomas using conventional
MRI images is often carried out as part of the preoperative
assessment in cases of glioma, which may or may not be done
in conjunction with magnetic resonance spectroscopy (MRS).
However, glioma grading using conventional MRI is some-
times unreliable due to the high false-positive rates arising
from the variability in tumour features [2, 3].
Over the last two decades, MRS has been increasingly used
for the grading of gliomas. Multiple previous studies have
corroborated and validated the relationship between the me-
tabolites detected by MRS and glioma grading [3–6]. Lipids
are one of the recognized metabolites consistently associated
with gliomas; previous studies [3–6] have utilized the mobile
lipid signals at 1.3 and 0.9 ppm as reference points. Although
MRS is considered a robust method for glioma grading [6], it
has several drawbacks. Multi-voxel MRS requires a long ac-
quisition time (6–10 minutes), which may give rise to motion
artefacts and patient discomfort. Image acquisition and spec-
tral differentiation may suffer from magnetic susceptibility
artefacts formed by the adjacent bones and haemorrhage, mo-
tion artefacts and poor shimming [3]. Single-voxel spectros-
copy (SVS), in particular, not only requires expensive soft-
ware, but is time-consuming for post-processing and result
interpretation [7].
The chemical shift in- and opposed-phase (IOP) sequence
is one of the gradient-echo (GE) MRI sequences, and it has
been clinically utilized for the detection of lipids in various
cond i t i on s , i n c l ud i ng ad r ena l adenoma , r ena l
angiomyolipoma, bone marrow pathology and whole-body
fat quantification [8–12]. A recent study has also shown its
usefulness in the detection of mobile lipids in intracranial le-
sions, including gliomas [13]. Elevated lipid levels in gliomas
have been reported in various studies [14]. In high-grade gli-
omas, elevated lipid levels appear as a higher signal loss in the
opposed-phase images. In this work, we attempt to take ad-
vantage of this physical phenomenon for grading of gliomas
based on lipid levels. Other advantages of this imaging se-
quence include shorter acquisition time (approximately
1 min), which is an advantage over MRS acquisition. This
sequence is also not susceptible to artefacts formed by adja-
cent bones and does not require expensive software applica-
tions [7, 15, 16].
In this study, we investigated the feasibility of using the
IOP imaging sequence to grade glioma. This work is divided
into two parts. The first involves a phantom study in which
parameters obtained using the IOP sequence are correlated to
lipid quantification using MRS. In the second section, the
feasibility of this method for glioma grading is investigated




Few lipid phantom studies have been carried out in which the
IOP sequence has been used for characterization [8, 13, 17].
To the best of the authors’ knowledge, no studies conducted to
date have used this sequence to investigate the correlation of
lipid components (ppm) obtained from SVS with lipid con-
centration (%). In the current work, a lipid phantom was con-
structed using SMOFlipid® 20 % (Fresenius Kabi, Richmond
Hill, Ontario, Canada), an emulsion used for infusion contain-
ing soya oil, medium-chain triglycerides, olive oil and fish oil.
The lipid phantom attempts to model the effects of low-lipid-
fraction tumours, such as gliomas, in an IOP sequence in
contrast to high-lipid-fraction tumours such as lipomas.
The lipid phantom was constructed using ten 50-ml (6.7-
cm height and 4.2-cm inner diameter) cylindrical bottles
placed within a larger rectangular (25.2×9.0×7.5 cm3) con-
tainer (Fig. 1). To prepare the solution for injection, the lipid in
SMOFlipid® 20 % was further diluted with water to obtain
nine 40-ml lipid phantom dilutions ranging from 20 to 1 %. A
tenth bottle was filled with pure water to act as a control. The
ten bottles were then submerged in a gelatin bath contained in
the rectangular container in order to augment magnetic field
homogeneity.
Coronal images of these phantoms were acquired with a
standard GE IOP sequence on a 3TMRI unit (Signa HDx; GE
Healthcare, Milwaukee, WI) using a dedicated head coil. Im-
aging parameters were as follows: 150 ms repetition time;
2.4 ms echo time for the in-phase, 5.8 ms echo time for the
opposed-phase; flip angle of 80°; number of averages=1;
250×250 mm2 field of view; matrix size of 256×256; and
5-mm slice thickness. Total scan time was 1 min 20 s.
Single-voxel spectroscopy (SVS) was then performed
using a point-resolved single-voxel spectroscopy (PRESS)
probe-p sequence with a short echo time of 35 ms and
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repetition time of 2000 ms. The axial, coronal and sagittal
multiplanar reconstructions of 3D T1 post-gadolinium fluid at-
tenuation inversion recovery (FLAIR) images were used to po-
sition a single voxel in the centre of the phantom,well away from
the side walls, with a volume of interest (VOI) of 1×1×1 cm3.
For analysis, the signal intensity (SI) of the IOP images was
measured using the OsiriX DICOM (v5, Pixmeo Sarl, Swit-
zerland). Three 3.0-mm3 round regions of interest (ROIs)
were placed in the centre of the phantom in the in-phase and
opposed-phase images, and the mean SI values were obtained.
The signal loss ratios (SLRs) were calculated using the fol-
lowing equation [18]:
Signal loss ratio SLRð Þ ¼ Signalin‐phase−Signalopposed‐phase
Signalin‐phase
The raw data (P-files) obtained from the SVS measure-
ments were post-processed using LCModel (v6.2,
LCMODEL Inc., Ontario, Canada) [19] to acquire the lipid
spectra of each dilution, where peaks of lipid components
were depicted at 0.9, 1.3, 1.6, 2.1, 2.3 and 2.8 ppm. The
LCModel settings of SPTYPE=‘lipid-8’ was chosen as the
basis set to adjust for spectra with lipid and water signals only.
The Cramér Rao lower bound (CRLB) [20] was used to quan-
tify the accuracy of the metabolite identification. Lipid con-
centrations with CRLB >20 % [19] were excluded from anal-
ysis. Statistical analysis was carried out using SPSS version 22
statistical software (IBM Corp., Armonk, NY). The Pearson
correlation test was used to test the correlation between the
SLR and various lipid concentrations, and statistical signifi-
cance was declared at p<0.05.
Clinical study
Full ethical approval was obtained from the local institutional
review board committee. All patients provided written in-
formed consent. This was a cross-sectional study of 22 pa-
tients with histologically proven gliomas who were initially
referred to our centre over a period from April 2011 to April
2015 for an assessment of intracranial space lesions. With the
use of a 3T MRI unit equipped with a dedicated head coil, a
standard tumour protocol was performed, with an additional
chemical shift GE IOP sequence obtained before contrast was
administered, followed by an SVS sequence after contrast
administration. Similar parameters were adopted for the IOP
sequence in the phantom study. None of the recruited glioma
patients had received any treatment prior to the study. SVS
was performed for the solid and cystic components of the
lesion using a 1500-ms repetition time, 35-ms echo time and
a VOI of 1×1×1 cm3. The solid portion was considered as the
portion of the tumour exhibiting an isointense signal on T1-
weighted (T1W) images and iso- to hyperintense signal on
T2-weighted (T2W) images, regardless of the presence or ab-
sence of tumour enhancement. The necrotic or cystic portion
was considered the portion of the tumour exhibiting a
hypointense signal on T1W images and hyperintense signal
on T2W images, which is similar to cerebrospinal fluid. Raw
data (P-files) obtained from the SVSmeasurements were post-
processed using a method similar to that used in the phantom
study.
A single neuroradiologist (KR) with 7 years of post-
specialisation experience and one trainee radiologist (AMK)
performed measurements of the SI of IOP images using the
Fig. 1 (a) Experimental setup for
cylindrical bottles containing nine
lipid dilutions and one control
phantom submerged in a gelatin
bath, with inset photo showing
the actual cylindrical bottle used
to contain the lipids. Fish oil
(arrow) was used as a marker to
distinguish the arrangement of the
phantom in the MRI image. (b)
In-phase and (c) opposed-phase
images of the lipid phantom.
Lipids at 0% indicates pure water,
which acts as a control
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OsiriX DICOM. The solid and cystic components were iden-
tified, and three ROIs were placed on the solid portion and
another three on the cystic portion (if available) in the in-phase
images. Placement of three ROIs was made to account for
variation in the internal heterogeneity of the intra-axial
masses. Opposed-phase images were then obtained with iden-
tical placement of the ROIs (Figs. 2 and 3). ROIs were kept to
around 3.0 mm3 in size. The mean SLRs (for solid and cystic
portions) were subsequently calculated and recorded.
Statistical analysis
Kruskal–Wallis and Mann–Whitney U tests were used to de-
termine significant differences in lipid concentration and SLR
among the lesions of various tumour grades and across all
tumour grades, respectively. A Pearson correlation test was
used to establish the correlation between the SLR and lipid
concentrations for the phantom study. Statistical significance
was declared at p<0.05. A three-group analysis was per-
formed in order to differentiate grades II, III and IV using R
software (R Foundation for Statistical Computing, Vienna,
Austria) [21]. The summary measures for the three grades
were performed based on the volume under the surface
(VUS) of the receiver operating characteristics (ROC) curve,
in order to evaluate the discriminative ability of the SVS and
SLR. VUS analysis was performed on lipid components that
demonstrated statistical significance in Kruskal–Wallis tests.
Histological analysis
The biopsy specimens were evaluated using gold-standard
histopathological analysis following the World Health Orga-
nization (WHO) guidelines [22]. According to guidelines, as-
trocytic tumour can be categorized as diffuse astrocytoma,
anaplastic astrocytoma or malignant glioblastoma (GBM) by
grades II, III or IV, respectively. We followed this designation
and graded tumours accordingly.
Results
Phantom study
Table 1 depicts the lipids detected in the phantom by
LCModel at selected lipid concentrations. Distinct lipid sig-
nals were measurable at around 0.9 ppm (Lip0.9 ppm) and
Fig. 2 Post-contrast T1W (a),
T2W (b), in-phase (c) and
opposed-phase (d) images of a
grade II diffuse astrocytoma, with
ROIs placed at the solid
component
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1.3 ppm (Lip1.3 ppm). A Pearson correlation test was run to
determine the relationships between the lipid concentrations
(in percentages), lipid components and SLR (Fig. 4). A posi-
tive correlation was found between lipid concentration and
SLR (r=0.981, n=9, p<.001). Thus, large values of lipid
concentrations are associated with large SLR values. There
were statistically significant positive correlations between lip-
id concentration and Lip1.3 ppm (r=0.989, n=9, p<.001) and
between lipid concentration and Lip0.9 ppm (r=0.789, n=9,
p=0.011). Therefore, high lipid concentrations are associated
Table 1 Lipid concentrations from the phantom





















Lip0.9 ppm 0.002 3 0.002 3 0.009 3 0.009 3 0.015 4 0.017 3 0.020 4 0.013 8 0.049 4 0.789*
Lip1.3 ppm 0.009 1 0.014 1 0.044 1 0.053 1 0.088 1 0.111 1 0.134 1 0.169 1 0.162 2 0.989*
Lip2.02 ppm 0.001 6 0.001 6 0.003 5 0.004 6 0.005 6 0.006 5 0.009 7 0.002 20 - >20 0.615
Lip2.23 ppm 0.001 6 0.001 5 0.004 4 0.004 5 0.005 5 0.007 5 0.011 6 0.004 14 - >20 0.764*
Lip2.75 ppm 0.001 6 0.012 4 0.005 4 0.005 4 0.008 4 0.007 4 0.011 5 0.007 6 0.007 9 0.327
IOP
SLR 0.084 0.109 0.270 0.330 0.429 0.463 0.503 0.527 0.539 0.981*
Conc concentrations of lipid components resonating at that particular ppm, SD standard deviation, IOP opposed-phase imaging, SLR signal loss ratio
obtained from IOP imaging, r Pearson correlation coefficient, correlating SLR and measured magnetic resonance spectroscopy (MRS) lipid component
concentration
Measurements for bottles containing water were excluded from compliance with CRLB (Cramér–Rao lower bound), as all standard deviations were
greater than 20 %
*Asterisks denote statistically significant difference (p<0.05) values for Pearson correlation test between lipid concentrations and lipid components
Fig. 3 Post-contrast T1W (a),
T2W (b), in-phase (c) and
opposed-phase (d) images of a
grade IV GBM, with ROIs placed
at the solid component
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with high concentrations of Lip0.9 ppm and Lip1.3 ppm. Sim-
ilarly, strong positive correlations were depicted between
SLR and Lip1.3 ppm (r=0.956, n=9, p<.001) and be-
tween SLR and Lip0.9 ppm (r=0.716, n=9, p=0.030),
where high SLR is associated with high concentrations
of Lip0.9 ppm and Lip1.3 ppm.
Clinical study
Demographic characteristics of the study population
The 22 patients with histologically proven glioma ranged in
age from 10 to 71 years (14 male, 8 female). Nine patients
Fig. 4 Scatter plots showing relationships between lipid concentration (%) and (a) Lip0.9 ppm, (b) Lip1.3 ppm and (c) SLR. Scatter plots showing the
relationship between SLR and (d) Lip0.9 ppm and (e) Lip1.3 ppm
2024 Eur Radiol (2016) 26:2019–2029
were diagnosed with grade II glioma, four with grade III gli-
oma and nine with grade IV GBM. The median length of time
between the MRI and histopathological examination was
0.84 months, and ranged from 1 day to 8 years. The median
time delay was longer for grade II gliomas, as these patients
were recruited on follow-up surveillance. Table 2 presents the
demographic characteristics of the respondents.
Astrocytic tumours and tumour grading
Histological diagnoses included diffuse astrocytoma (n=5),
pilomyxoid astrocytoma (n=1), gemistocytic astrocytoma
(n = 1 ) , o l i g o d en d r o g l i oma (n = 1 ) , a n a p l a s t i c
oligodendroglioma (n=4), oligoastrocytoma (n=1) and
GBM (n=9). Two of the tumours were infratentorial in loca-
tion (pilomyxoid astrocytoma in the right cerebellar vermis
and diffuse astrocytoma in the brainstem) and the rest were
located supratentorially. Grade II and III oligodendrogliomas
were located in the frontal lobe (n=2), parietal lobe (n=3) and
left basal ganglia (n=1). In contrast, the astrocytomas, includ-
ing GBM, were found at various sites (involving all cerebral
lobes but the occipital lobe), with five of the tumours demon-
strating corpus callosum involvement (three were GBMs).
Descriptive analysis of MRS-detected lipids
Table 3 shows the descriptive data of various lipid compo-
nents measured by LCModel, factored by WHO tumour
grades II, III and IV. Lipids and macromolecules with peaks
at Lip1.3a ppm, Lip2.0 ppm (lipid signals around 1.3 ppm and
2.0 ppm, respectively, in brain spectra) and Lip1.3a + Lip1.3b
ppm (sum concentration of lipid signals resonating at 1.28–
1.30 ppm) demonstrated statistically significant differences (p
<0.05) across tumour grades (Table 3). The concentrations of
Lip1.3a ppm and Lip1.3a + Lip1.3b ppm generally increased
according to tumour grade. However, Lip2.0 ppm showed a
slight dip from grade II to III, before increasing again from
grade III to IV.
Analysis of the signal loss ratio in chemical shift IOP
sequence
Table 4 shows the statistical descriptions and test results of
SLR in the solid and cystic components of the tumours, fac-
tored by WHO tumour grades II, III and IV. Descriptive data
are provided as median and inter-quartile range (IQR) values.
Note that IQR values are not available for grade III, as there
were only four patients with this grade. For the solid compo-
nent, there was a general increase in SLR with increasing
tumour grade, and a similar pattern was observed in the cystic
component.
Comparison of classification probabilities between the two
imaging techniques (SVS versus IOP imaging)
in discriminating brain gliomas of different grades
The classification probabilities of the SVS and SLR were
evaluated using three-group VUS analysis. VUS analysis is
able to provide better accuracy for discriminating the three
glioma grades (II, III and IV) than conventional binary class
ROC analysis. Using the VUS method, we obtained VUS
estimates and upper and lower cut-point values for the param-
eters measured (in this case, SVS and SLR). Higher VUS
estimates indicate that the parameter has a higher discrimina-
tive power. Parameters with values smaller than the lower cut-
points are classified as grade II, while those larger than the
upper cut-points are classified as grade IV. Values within the
upper and lower cut-points are classified as grade III. This
method of analysis also provides the probability of correctly
classifying the glioma grades.
Table 5 shows the VUS analysis on SVS and SLR. For
SVS, only lipids and macromolecules with significant differ-
ences across tumour grades and with consistent increasing
order across tumour grades were included in the analysis.
The distributions of lipid concentrations of Lip1.3a ppm
and Lip1.3a + Lip1.3b ppm detected by LCModel according
to the WHO actual grade are shown as boxplots in Fig. 5a and
Table 2 Patient demographics,
with astrocytic tumours and
tumour grading
Grade II Grade III Grade IV
Number of patients 9 4 9
Gender Male 5 (55.6 %) 3 (75.0 %) 6(66.7 %)
Female 4 (44.4 %) 1 (25.0 %) 3(33.3 %)
Age [mean (range), years] Male 37.4 (15–61) 46.3 (24–67) 57.5 (42–71)
Female 32.5 (17–45) 35.0 (35) 43.0 (10–65)
Tissue sampling (biopsy) Total or partial resection 5 4 6
Stereotactic biopsy 4 0 3
Time delay between MRS and histology
[median (range), months]
2 (0.03–96.00) 1.5 (0.33–5.00) 0.6 (0.07–17.0)
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b. The concentrations of Lip1.3a ppm and Lip1.3a + Lip1.3b
ppm generally increase according to the tumour grade.
Figure 5c and d depicts the distributions of signal loss ratios
acquired from IOP imaging according to the WHO actual
grade in the form of boxplots. The ratios of solid and cystic
portions generally increase according to the tumour grade.
Discussion
Multiple studies have been conducted in efforts to develop a
non-invasivemethod for the grading of gliomas.Most of these
studies involved the utilization of both conventional and ad-
vancedMRI sequences, namelyMRS, diffusion-weighted im-
aging (DWI), perfusion imaging and diffusion kurtosis imag-
ing, in defining tumour morphology and glioma grade [2, 23].
Acknowledging the major role of lipids in tumour grading
shown in previous studies [10, 13, 14], we addressed this issue
by utilizing IOP sequences, which have a shorter acquisition
time, in order to quantify the signal loss in proportion to the
presence of lipid components. While previous phantom stud-
ies have used a fat–water interface method to obtain the fat
fraction against the SI curve [8, 24, 25], our phantom uses
water-soluble lipids to achieve lipid quantification. The pres-
ence of Lip0.9 ppm and Lip1.3 ppm depicted by MRS are
reflected on the IOP images by means of SLR, as SVS was
conducted on the phantom after the sequences were per-
formed. This demonstrates that small lipid fractions are detect-
able by IOP imaging, thus representing a viable means of
glioma detection in the clinical setting, as Lip0.9 ppm and
Lip1.3 ppm have been reported to be associated with the di-
agnosis of glioma [3–6].
The lipid components obtained from SVS in the phantom
study differed from those in the clinical study, as different
basis sets were used. The phantom study used the special lipid
settings to adjust for lipid and water components only, while
the clinical study utilized standard brain spectra. The differ-
ences were obvious in terms of Lip1.3 ppm of the phantom
Table 4 SLR of solid and cystic
components in grade II to grade
IV glioma
Grade II (n=9) Grade III (n=4) Grade IV (n=9) Kruskal–Wallis
Median IQR Median IQR Median IQR
Solid 0.040 0.034 0.089 - 0.098 0.037 0.001*
Cystic 0.018 0.048 0.081 - 0.093 0.063 0.033*
Note: rightmost columns showing the significant values of the Kruskal Wallis tests
Asterisks (*) denote statistically significant difference (p<0.05) values. SLR signal loss ratio
Table 3 Median and IQR of lipid concentrations using SVS for WHO grade II to grade IV gliomas
Lipid Components Grade II (n=9) Grade III (n=3) Grade IV (n=9) Kruskal–Wallis
Median IQR Median IQR Median IQR
Lip1.3a ppm 3.374 6.404 5.363 - 11.516 8.402 0.029*
Lip1.3b ppm 0.000 1.896 0.000 - 0.734 2.681 0.520
Lip0.9 ppm 2.033 1.737 1.112 - 3.681 3.36 0.050
MM0.9 ppm 1.402 2.561 3.226 - 1.732 1.939 0.232
Lip2.0 ppm 0.775 1.083 0.652 - 2.099 2.193 0.019*
MM2.0 ppm 2.135 2.839 3.028 - 2.160 4.652 0.890
MM1.2 ppm 0.525 0.655 0.642 - 0.483 0.834 0.827
MM1.4 ppm 0.584 2.499 2.226 - 0.300 2.792 0.584
MM1.7 ppm 0.507 0.883 2.020 - 0.684 1.169 0.278
Lip1.3a + Lip1.3b ppm 4.679 7.422 5.363 - 12.186 11.137 0.027*
MM1.4 + Lip1.3a + Lip1.3b + MM1.2 ppm 8.969 10.046 17.615 - 15.459 11.246 0.058
MM0.9 + Lip0.9 ppm 3.378 3.474 4.338 - 5.965 3.066 0.088
MM2.0 + Lip2.0 ppm 3.740 3.205 4.269 - 5.967 4.001 0.315
Descriptive data are provided asmedian and inter-quartile range (IQR) values. Note that there are no IQR values available for grade III, as there were only
four patients with this grade
*p<0.05 across all tumour grades (grades II, III and IV), with the rightmost column showing the values of the Kruskal–Wallis tests
MRS results are not available for one grade III patient, owing to the poor quality of the spectra
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MRS and Lip1.3a + Lip1.3b ppm obtained from clinical
MRS. Lip1.3 ppm in the phantom study refers to a lipid signal
around 1.3 ppm, whereas Lip1.3a + Lip1.3b ppm acquired
from brain spectra resonates at 1.28–1.30 ppm, which was
found to be enriched in neural stem cells [26].
Our clinical findings suggest that SLR can serve as a pa-
rameter for discriminating between glioma grades (II, III and
IV). The SLR at the solid tumour portion was the best measure
for differentiation, using optimal cut-points of 0.064 and
0.086, meaning that SLR values smaller than 0.064 are clas-
sified as grade II while SLR values larger than 0.086 are clas-
sified as grade IV. The values that lie between the cut-points
are classified as grade III. Correct classification probability for
grades II and IV was fairly high (SII =1, SIV=0.89), but was
poorer for grade III (SIII=0.50), which may be due to the
small sample size (n =4). A different approach was
implemented for the evaluation of glioma grading, in which
a three-group ROC analysis [21] was used rather than a typical
binary ROC method, thus providing a more detailed analysis.
To the best of our knowledge, there are no data yet available
involving glioma studies using a three-group analysis
approach.
This current study is the first to use this sequence for grad-
ing of intracranial glioma. Although some studies have eval-
uated the chemical shift sequence along with MRS [8, 27], the
lipid types causing the signal loss were never proven to be
similar to the lipid components identified in clinical MRS,
due to MRS limitations related to intra-abdominal pathology.
The limitation in the present study is the very small sample
size, especially the grade III subsample. Because of the fast
progression that occurs from grade III to grade IV, it was
difficult to acquire grade III patients.
Fig. 5 Boxplots of lipid
components acquired from MRS
in different concentrations. (a)
Lip1.3a ppm, (b) Lip1.3a +
Lip1.3b ppm and SLR obtained
from IOP imaging: (c) solid
portion and (d) cystic portion of
the tumour across WHO grade II
to IV glioma
Table 5 Results of VUS analysis (non-parametric approach) for differentiating grades II, III and IV
Measurement VUS 95 % CI Lower cut-point Upper cut-point Correct classification probability
SII SIII SIV
Lip1.3a ppm 0.276 0.033–0.527 3.374 7.291 0.556 0.333 0.889
Lip1.3a + Lip1.3b ppm 0.350 0.092–0.667 4.679 7.685 0.556 0.333 0.889
SLR (solid) 0.639 0.291–0.904 0.064 0.086 1.000 0.500 0.889
SLR (cystic) 0.560 0.145–0.831 0.027 0.062 0.833 0.500 1.000
VUS volume under surface of the receiver operating characteristic curve (ROC), CI confidence interval, SLR signal loss ratio, SII correct classification
probability of grade II, SIII correct classification probability of grade III, SIV correct classification probability of grade IV
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As this research study involves a novel MRI technique that
was performed at a single institution, only a small population
was studied. We propose a larger patient sample using
multicentre participation to ensure a representative distribu-
tion of the population among which results will be generalized
or transferred. Comparisons of the IOP method to other
established methods such as diffusion-weighted imaging
(DWI), perfusion imaging and diffusion kurtosis imaging in
the grading and prognostication of glioma would also be
advantageous.
Conclusions
The findings in this study provide a more comprehensive
characterization of lipid quantification through the use of
chemical shift GE IOP imaging, which may represent an al-
ternative to the MRS technique. The chemical shift GE IOP
imaging method supports the findings of previous studies re-
vealing mobile lipids in higher-grade gliomas [14]. The three-
group VUS analysis enabled a better evaluation of the dis-
criminative ability of the SVS and SLR parameters among
tumour grades (II, III and IV) compared to that of binary
analysis (high grade vs. low grade) commonly performed in
other studies [4–6]. This novel technique of using chemical
shift GE IOP imaging has a promising future, with potential
application for glioma staging in a research capacity.
Implications for patient care
This IOP sequence has the ability to grade gliomas with
shorter imaging time thanMRS. The IOP sequence may prove
useful for patients who are unable to remain immobile in the
scanner for long periods.
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